Market Overview

UPDATE: JMP Securities Initiates Coverage On Ardelyx Following Valuation Analyses


In a report published Monday, JMP Securities analyst Michael G. King initiated coverage on Ardelyx (NASDAQ: ARDX) with a Market Outperform rating and $26.00 price target.

In the report, JMP Securities noted, “Initiating coverage of Ardelyx, the industry leader in the development of non-absorbed drugs, with a Market Outperform rating and $26 price target based on the synthesis of our DCF and SOTP valuation analyses.

"The company completed its IPO transaction on June 19, 2014. Ardelyx is utilizing its first-in-class chemistry to discover and develop non-absorbed, small molecule compounds that block the absorption of a variety of ions (e.g., sodium, potassium, calcium) across the lumen of the gastrointestinal (GI) tract for the treatment of cardiorenal, GI, and metabolic diseases. The foundation of Ardelyx is built upon the discoveries of co-founder and Chief Scientific Officer, Dominique Charmot, PhD, a successful entrepreneur in the biotech space who founded Ilypsa, a company that developed a non-absorbed phosphate binder that was eventually sold to Amgen for $420MM in 2007.”

Ardelyx closed on Friday at $17.75.

Latest Ratings for ARDX

Aug 2018JefferiesInitiates Coverage OnBuy
Aug 2018CitigroupMaintainsBuyBuy
Oct 2017CitigroupMaintainsBuy

View More Analyst Ratings for ARDX
View the Latest Analyst Ratings

Posted-In: JMP Securities Michael G. KingAnalyst Color Initiation Analyst Ratings


Related Articles (ARDX)

View Comments and Join the Discussion!

Latest Ratings

INTUMorgan StanleyMaintains245.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Trader Essentials
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

UPDATE: Teva Announces FDA Acceptance of NDA For Inhaler

UPDATE: Bona Film Group Announces Chair, CEO Mr. Yu Dong to Buy 21st Century Fox's Stake in Bona Film, Will Pay $5.90/ADS